Even when treatment puts stage I and II melanoma into remission, 39% of patients still face recurrence or another event by the 5 year mark, which makes “no evidence of disease” only half the picture. The pattern of relapse is equally specific, with the brain among the most frequent distant sites and thicker primary tumors showing recurrence rates up to 1.5 to 2 times higher than thinner ones. We will connect staging, surveillance choices like CT or PET and emerging tools such as ctDNA to the real timelines and risk signals clinicians track.
Key Takeaways
- 61% of patients with stage I–II melanoma had no evidence of disease 5 years after treatment in a large observational cohort—indicating 39% experienced recurrence or subsequent events by 5 years
- Brain is among the most frequent sites of recurrence for patients who relapse with distant disease—central nervous system involvement is a major recurrence pattern
- 1.5–2x higher recurrence rates in patients with thicker primary melanomas compared with thinner tumors—thickness is a strong predictor of relapse risk
- NCCN recommends consideration of periodic imaging (e.g., CT/PET) for higher-risk melanoma during follow-up—aimed at earlier detection of recurrence
- ASCO guidance supports scheduled follow-up (clinical visits and imaging when indicated) to enable earlier detection of recurrence—structured surveillance is an evidence-based component of care
- European Society for Medical Oncology (ESMO) recommends follow-up after adjuvant therapy with regular clinical evaluations and imaging based on risk—standardizing recurrence detection
- In a study of stage III melanoma, ctDNA positivity was reported to be strongly associated with disease recurrence and worse relapse-free survival—ctDNA serves as a high-specificity recurrence risk indicator
- In a landmark ctDNA study, recurrence was detected earlier by ctDNA than by conventional imaging in many cases—demonstrating lead time for relapse prediction
- BRAF V600E mutation occurs in about 40–50% of cutaneous melanomas—affecting recurrence risk biology and therapy choices
- In adjuvant trials, landmark 2-year endpoints (e.g., relapse-free survival at 2 years) quantify recurrence impact—allowing numeric comparison across therapies
- In KEYNOTE-054, pembrolizumab improved distant metastasis-free survival vs placebo in stage III melanoma—measured by hazard ratios and event rates
- Adjuvant nivolumab in resected stage IIIB/C and stage IV melanoma lowered the risk of recurrence compared with ipilimumab; hazard ratio reported near 0.65 in CheckMate 238—measurable recurrence impact
- Globally, melanoma deaths are about 57,000 per year (2018 GLOBOCAN estimate)—relapse and progression contribute to mortality
- The U.S. has approximately 21,000–24,000 melanoma deaths per year historically in SEER/CDC-based reporting—reflecting ongoing relapse-related mortality
- The CDC estimated roughly 45,000 hospitalizations for melanoma in recent years (trend-dependent)—hospital recurrence/progression contributes to acute care utilization
Most early stage melanoma patients stay disease free at five years, but thicker and node positive disease increases recurrence risk.
Related reading
01 · Category
Clinical Outcomes9 stats
01
61% of patients with stage I–II melanoma had no evidence of disease 5 years after treatment in a large observational cohort—indicating 39% experienced recurrence or subsequent events by 5 years
02
Brain is among the most frequent sites of recurrence for patients who relapse with distant disease—central nervous system involvement is a major recurrence pattern
03
1.5–2x higher recurrence rates in patients with thicker primary melanomas compared with thinner tumors—thickness is a strong predictor of relapse risk
04
The American Joint Committee on Cancer (AJCC) 8th edition staging system reports that stage IV melanoma has the highest risk of recurrence and progression—reflecting markedly worse outcomes at advanced stage
05
In a population-based analysis, regional lymph node metastasis at diagnosis increased the risk of recurrence and death compared with no metastasis—node-positive disease is associated with higher relapse
06
Approximately 8% of patients with localized melanoma develop distant metastases during follow-up in SEER-based analyses—distant spread implies recurrence after initial treatment
07
In melanoma, Breslow thickness stratification (e.g., T1 <0.8 mm vs higher thickness) corresponds to increasing recurrence risk—measured via stage-specific recurrence rates in cohorts
08
Higher mitotic rate is associated with increased recurrence risk in melanoma; mitotic rate categories show increasing hazards for relapse—measured in clinicopathologic studies
09
In a meta-analysis of sentinel lymph node status, SLN positivity increases risk of recurrence compared with SLN negativity—measurable via pooled hazard ratios
Interpretation
Clinical Outcomes Interpretation
In clinical outcomes for melanoma, the overall picture is that even after treatment most early stage patients still have a meaningful recurrence risk, since 39% of stage I to II patients show a recurrence or subsequent event by 5 years, with relapse risk rising further when factors like greater thickness, higher mitotic rate, and node positivity are present.
02 · Category
Surveillance & Care Pathways8 stats
01
NCCN recommends consideration of periodic imaging (e.g., CT/PET) for higher-risk melanoma during follow-up—aimed at earlier detection of recurrence
02
ASCO guidance supports scheduled follow-up (clinical visits and imaging when indicated) to enable earlier detection of recurrence—structured surveillance is an evidence-based component of care
03
European Society for Medical Oncology (ESMO) recommends follow-up after adjuvant therapy with regular clinical evaluations and imaging based on risk—standardizing recurrence detection
04
For melanoma patients at higher risk of recurrence, PET/CT is used to detect asymptomatic relapse—PET/CT is a key modality for surveillance
05
In a multicenter analysis of melanoma follow-up testing, routine lab tests (e.g., LDH) were not consistently predictive for recurrence compared with clinical assessment and imaging—indicating limited surveillance yield from nonspecific biomarkers
06
PET/CT sensitivity for detecting metastatic recurrence is quantified in meta-analyses (e.g., ranges around mid-80% to low-90% depending on patient selection)—supporting imaging-based surveillance
07
CT imaging is commonly used for recurrence detection; contrast-enhanced CT protocols are standard in oncology follow-up—providing measurable detection of structural recurrence
08
Ultrasound of nodal basins is used in surveillance strategies for melanoma patients at elevated risk—non-invasive monitoring supports early detection
Interpretation
Surveillance & Care Pathways Interpretation
For higher-risk melanoma, major guidelines emphasize structured surveillance with imaging such as PET or CT, with PET/CT sensitivity for metastatic recurrence reported in the mid 80% to low 90% range, while nonspecific routine labs like LDH have shown limited predictive value, reinforcing that care pathways should focus on risk based imaging rather than biomarkers alone.
03 · Category
Biomarkers & Risk Stratification12 stats
01
In a study of stage III melanoma, ctDNA positivity was reported to be strongly associated with disease recurrence and worse relapse-free survival—ctDNA serves as a high-specificity recurrence risk indicator
02
In a landmark ctDNA study, recurrence was detected earlier by ctDNA than by conventional imaging in many cases—demonstrating lead time for relapse prediction
03
BRAF V600E mutation occurs in about 40–50% of cutaneous melanomas—affecting recurrence risk biology and therapy choices
04
NRAS mutations are reported in about 15–25% of melanomas—relevant to recurrence biology and treatment selection
05
TILs (tumor-infiltrating lymphocytes) assessment is used for prognostication; higher TIL levels have been associated with better recurrence-free outcomes in multiple cohorts—immunologic state stratifies recurrence risk
06
Tumor ulceration is present in roughly 30–40% of primary melanomas in published series—ulceration is a key predictor of recurrence risk
07
LDH elevation is associated with worse outcomes; in advanced melanoma trials, elevated LDH defines higher-risk groups—indicating a measurable recurrence/progression risk marker
08
AJCC T stage improvements in 8th edition incorporate mitotic rate where available; higher T stages correspond to increased recurrence risk—staging captures measurable relapse propensity
09
Gene expression profiling of melanoma has been associated with recurrence prediction; recurrence risk scores provide measurable stratification in studies
10
In a pooled analysis of ctDNA in melanoma, recurrence occurred far more frequently among ctDNA-positive patients than ctDNA-negative patients (large effect sizes reported)—quantifying predictive performance
11
In studies of plasma tumor mutational burden (TMB) or genomic indicators, higher mutation burden correlates with improved response to immunotherapy but also reflects aggressive biology—affecting recurrence risk stratification
12
In melanoma, serum S100B is elevated in a fraction of patients and correlates with prognosis; studies report measurable associations with recurrence risk
Interpretation
Biomarkers & Risk Stratification Interpretation
Across biomarkers in melanoma risk stratification, several tests show clear separation of recurrence risk such as ctDNA positivity signaling a strongly higher likelihood of relapse in stage III disease while T stage and tumor ulceration appear in about 40 percent and 30 to 40 percent of cases respectively, and with BRAF V600E present in roughly 40 to 50 percent and NRAS in 15 to 25 percent, supporting a consistent trend that measurable molecular and clinical features can identify patients at higher recurrence risk before conventional imaging.
More related reading
04 · Category
Treatment Impact13 stats
01
In adjuvant trials, landmark 2-year endpoints (e.g., relapse-free survival at 2 years) quantify recurrence impact—allowing numeric comparison across therapies
02
In KEYNOTE-054, pembrolizumab improved distant metastasis-free survival vs placebo in stage III melanoma—measured by hazard ratios and event rates
03
Adjuvant nivolumab in resected stage IIIB/C and stage IV melanoma lowered the risk of recurrence compared with ipilimumab; hazard ratio reported near 0.65 in CheckMate 238—measurable recurrence impact
04
In COMBI-AD, the primary endpoint relapse-free survival showed a hazard ratio around 0.47—quantifying recurrence reduction for BRAF-mutant stage III
05
In COMBI-AD, 5-year relapse-free survival for dabrafenib/trametinib is reported in the mid-50% range compared with low-40% for placebo—measurable 5-year recurrence reduction
06
Adjuvant interferon alfa-2b historically improved relapse-free survival modestly in high-risk melanoma—effect sizes measured in randomized trials (hazard ratios in the literature)
07
The estimated 3-year recurrence-free survival benefit in modern adjuvant trials for stage III disease is on the order of ~10–15 percentage points compared with control—quantifying recurrence reduction
08
For patients with resected high-risk melanoma, adjuvant checkpoint inhibitors have reported 2-year relapse-free survival rates exceeding 60% in several trials—measurable recurrence outcomes
09
For stage III melanoma treated with adjuvant anti–PD-1, relapse-free survival curves show separation early and persist over years—demonstrating sustained recurrence risk reduction
10
In CheckMate 238, nivolumab improved relapse-free survival compared with ipilimumab; reported hazard ratio around 0.65 in updated analyses—measurable reduction in recurrence
11
In stage III melanoma treated with adjuvant anti–PD-1, 5-year relapse-free survival is reported in the mid-50% range in some datasets—quantifying long-term recurrence outcomes
12
In KEYNOTE-054, 3-year relapse-free survival for pembrolizumab exceeded 60% in updates—quantifying recurrence impact over multiple years
13
In CheckMate 238 updates, 4-year outcomes for relapse-free survival show improved disease control vs comparator—measured with survival probabilities in trial follow-up reports
Interpretation
Treatment Impact Interpretation
Across modern adjuvant melanoma trials, treatment impact is clearly measurable with checkpoint inhibitors cutting recurrence risk by about half on key endpoints, such as COMBI-AD’s relapse free survival hazard ratio near 0.47 and durable 2 year relapse free survival rates above 60 percent in several stage III settings, showing sustained reductions in recurrence rather than short term control.
05 · Category
Epidemiology & Burden4 stats
01
Globally, melanoma deaths are about 57,000 per year (2018 GLOBOCAN estimate)—relapse and progression contribute to mortality
02
The U.S. has approximately 21,000–24,000 melanoma deaths per year historically in SEER/CDC-based reporting—reflecting ongoing relapse-related mortality
03
The CDC estimated roughly 45,000 hospitalizations for melanoma in recent years (trend-dependent)—hospital recurrence/progression contributes to acute care utilization
04
In Europe, melanoma is among the leading cancers in incidence; GLOBOCAN provides country-level incidence counts that sum to hundreds of thousands annually—indicating large recurrence-detection need
Interpretation
Epidemiology & Burden Interpretation
From a global standpoint, about 57,000 melanoma deaths each year and roughly 21,000 to 24,000 in the US underscore that relapse and progression are major ongoing drivers of the disease burden, further reflected by about 45,000 melanoma hospitalizations and high, multi country incidence levels reported in Europe by GLOBOCAN.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Melanoma Recurrence Statistics. Gitnux. https://gitnux.org/melanoma-recurrence-statistics
MLA
Aisha Okonkwo. "Melanoma Recurrence Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/melanoma-recurrence-statistics.
Chicago
Aisha Okonkwo. 2026. "Melanoma Recurrence Statistics." Gitnux. https://gitnux.org/melanoma-recurrence-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+35 additional datasets cited (not shown individually)